Symposiums

This symposium provided an overview of the current and future technologies and treatments used in the field of allergen immunotherapy (AIT).

Hereditary angioedema manifests as recurrent self-limiting episodes of angioedema, affecting the skin or mucosal tissues.

Prof Robin Foà opened the symposium by highlighting how improving healthcare and an ageing population are increasing the burden on healthcare resources…

A recent symposium at the European Hematology Association (EHA) congress, chaired by Prof Eva Kimby, explored the changing paradigms in the treatment of…

Several rare haematological diseases are linked to bone marrow failure (BMF). This symposium provided the latest scientific insights into the different…

The treatment landscape for patients with multiple myeloma (MM) is constantly evolving. Over the past decade, the introduction of novel agents including…

Three biosimilar products are now licensed for the treatment of rheumatic diseases in Europe. The European Medicines Agency (EMA) requires that similarity between a biosimilar and its reference product is demonstrated using a rigorous, stepwise process that includes extensive physicochemical and biological analytical testing, non-clinical pharmacology, clinical evaluations, and pharmacovigilance plans. Each

Prof Peter Taylor opened the symposium focussed on optimisation of treatment for rheumatoid arthritis (RA) at each stage of the patient’s journey. Prof…